Pomalidomide

For research use only.

Catalog No.S1567 Synonyms: CC-4047

66 publications

Pomalidomide Chemical Structure

CAS No. 19171-19-8

Pomalidomide (CC-4047) inhibits LPS-induced TNF-α release with IC50 of 13 nM in PBMCs. Pomalidomide can be utilized in PROTAC as a ligand for targeting E3 ligase and inhibiting the E3 ligase protein cereblon (CRBN). Pomalidomide promotes apoptosis and cell cycle arrest.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 91 In stock
USD 70 In stock
USD 120 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Pomalidomide has been cited by 66 publications

Purity & Quality Control

Choose Selective E3 ligase Ligand Inhibitors

Biological Activity

Description Pomalidomide (CC-4047) inhibits LPS-induced TNF-α release with IC50 of 13 nM in PBMCs. Pomalidomide can be utilized in PROTAC as a ligand for targeting E3 ligase and inhibiting the E3 ligase protein cereblon (CRBN). Pomalidomide promotes apoptosis and cell cycle arrest.
Features A derivative of thalidomide and up to 10,000 times more potent than thalidomide.
Targets
CRBN [5]
()
TNF-α [1]
(PBMCs)
13 nM
In vitro

Pomalidomide inhibits lipopolysaccharide (LPS) stimulated TNF-alpha release in human PBMC and in human whole blood with IC50 values of 13 nM and 25 nM, respectively. [1] Pomalidomide inhibits the growth of T regulatory cells which is stimulated by IL-2 with an IC50 of ~1 μM. [2] Treatment with Pomalidomide (6.4 nM-10 μM) increases the production of IL-2 in human peripheral blood T cells, and is slightly more potent in the CD4+ subset than in the CD8+ subset. Pomalidomide is significantly more potent than CC-5013 at elevating IL-2, IL-5, and IL-10 levels, but only slightly more potent than CC-5013 at elevating IFN-γ levels. Pomalidomide enhances SEE and Raji cells induced AP-1 transcriptional activity in Jurkat cells in a dose-dependent manner, with a maximal enhancement of 4-fold at 1 μM. [3] Exposure of Raji cells to various concentrations of Pomalidomide (2.5-40 μg/mL) for 48 hours leads to a significant decrease in cell proliferation and DNA synthesis. There is a reduction of ~40% compared to vehicle-treated controls. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MOLP-8 NFrxTmREgXSxdH;4bYNqfHliQYPzZZk> NWfWNGl7OTBizszN NVuwSpEzOjRiaB?= MVjwc5RmdnSueTDheYdu\W62czDkbZJm[3RiYX7kJIlv\Gm{ZXP0JG1OKGOnbHygb4ltdGmwZzDifUBUSVJ? MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjN|OEK3N{c,OjZ|M{iyO|M9N2F-
J-CD38 M2C5TmN6fG:2b4jpZ4l1gSCDc4PhfS=> M{e5[FExKM7:TR?= M1y5XlI1KGh? NGjWeYdxd3SnboTsfUBifWevZX70d{BlcXKnY4SgZY5lKGmwZHny[YN1KE2PIHPlcIwhc2mubHnu[{BjgSCVQWK= MkPvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ|M{iyO|MoRjJ4M{O4Nlc{RC:jPh?=
R-CD38 MonPR5l1d3SxeHnjbZR6KEG|c3H5 MmDlNVAh|ryP NWi4eGZNOjRiaB?= NYi1Npg6eG:2ZX70cJkh[XWpbXXueJMh\Gm{ZXP0JIFv\CCrbnTpdoVkfCCPTTDj[YxtKGurbHzpcoch[nliU1HS NGTucZA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkOzPFI4Oyd-Mk[zN|gzPzN:L3G+
BC-3 NUDjTFVxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUGzPU0yOjVyIH7N NVPDNFlGPSCm MVvEUXNQyqB? M4fRc2lEPTB;MUC3JI5ONCCrbnjpZol1eyClZXzsJGlEPTB;MUC3JI5ONCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? NYP1dFRGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xNVk6OzlpPkK2NVE6QTN7PD;hQi=>
BCBL-1 NGj3dmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;QNJo{QS1zMkWwJI5O MVe1JIQ> NYThfpdiTE2VT9Mg M1n6bmlEPTB;N{Sgcm0tKGmwaHnibZR{KGOnbHygeoli[mmuaYT5JIRwe2ViZHXw[Y5l\W62bIm= NFzteXA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGxPVk{QSd-Mk[xNVk6Ozl:L3G+
JSC-1 MnjES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{fwe|M6NTF{NUCgcm0> NVm4Z|JxPSCm M3PRbGROW00EoB?= MnrSTWM2OD1|NDDuUUwhcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= M2DJOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUG5PVM6Lz5{NkGxPVk{QTxxYU6=
VG-1 Mk[0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HuXFM6NTF{NUCgcm0> MX:1JIQ> NG\t[YZFVVORwrC= NVLxWnNtUUN3ME2xNFEhdk1uIHnubIljcXS|IHPlcIwhfmmjYnnsbZR6KGSxc3Wg[IVx\W6mZX70cJk> NVv0R5BYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xNVk6OzlpPkK2NVE6QTN7PD;hQi=>
UMPEL-1 M2DoXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETVcHE{QS1zMkWwJI5O M1f2WlUh\A>? MnO4SG1UV8Li MXzJR|UxRTN{IH7NMEBqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 M3vFUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUG5PVM6Lz5{NkGxPVk{QTxxYU6=
UMPEL-3 NVfld5VpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYmzPU0yOjVyIH7N M4fyXFUh\A>? M1rJSmROW00EoB?= MmnJTWM2OD1zMUGgcm0tKGmwaHnibZR{KGOnbHygeoli[mmuaYT5JIRwe2ViZHXw[Y5l\W62bIm= M17DdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUG5PVM6Lz5{NkGxPVk{QTxxYU6=
BC-1 M{nDcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzxe2ViOzlvMUK1NEBvVQ>? NGfIS|E2KGR? NGTiXHhFVVORwrC= M1n0WmlEPTB;N{S0JI5ONCCrbnjpZol1eyClZXzsJJZq[WKrbHn0fUBld3OnIHTldIVv\GWwdHz5 NVnpVlZWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xNVk6OzlpPkK2NVE6QTN7PD;hQi=>
BCP-1 MonjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfmPJI{QS1zMkWwJI5O MWS1JIQ> M1jlXGROW00EoB?= MX3JR|UxRTN7NjDuUUwhcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= M4\xelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUG5PVM6Lz5{NkGxPVk{QTxxYU6=
APK-1 Mn;WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrkdFdnOzlvMUK1NEBvVQ>? NGjsXHc2KGR? M2XzdmROW00EoB?= NIHDUnNKSzVyPUKyOkBvVSxiaX7obYJqfHNiY3XscEB3cWGkaXzpeJkh\G:|ZTDk[ZBmdmSnboTsfS=> MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjFzOUmzPUc,OjZzMUm5N|k9N2F-
RPMI8226  MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTidJAxNjBzLUWwJO69VQ>? NWTrVm5MPDhiaB?= M1XBWmROW00EoB?= MVnJR|UxRThizszN NWDqPVFyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wPVc5PzJpPkK2NFk4QDd{PD;hQi=>
OPM2  MkWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfvNYFJOC5yMT21NEDPxE1? Mnu1OFghcA>? NFO4ZXRFVVORwrC= NIfjeZRKSzVyPUGwJO69VQ>? MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB7N{i3Nkc,OjZyOUe4O|I9N2F-
RPMI8226  M17vOWZ2dmO2aX;uJGF{e2G7 MX[xNEDPxE1? M3XX[FQ5KGh? NYnweHpWTE2VT9Mg NU\QdJN1e3S{ZX7neIhmdnNiY4n0c5Bt[XOvaXOtcpVkdGWjcjDzbJV1fGyrbnegc4YhdVSRUjDhcoQheC2vVF;SJJBzd3SnaX6= NFjwXJY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkC5O|g4Oid-Mk[wPVc5PzJ:L3G+
OPM2  NVnkNGlDTnWwY4Tpc44hSXO|YYm= NILISVMyOCEQvF2= MVi0PEBp NUe4bph4TE2VT9Mg NYLxcnpIe3S{ZX7neIhmdnNiY4n0c5Bt[XOvaXOtcpVkdGWjcjDzbJV1fGyrbnegc4YhdVSRUjDhcoQheC2vVF;SJJBzd3SnaX6= NYXtNpBiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wPVc5PzJpPkK2NFk4QDd{PD;hQi=>
RPMI8226 M2XafmZ2dmO2aX;uJGF{e2G7 MVqwMlEuOTBizszN MlXaOEBp NXPRe4hXTE2VT9Mg M4nCNIlv[3KnYYPld{BXTUeIIH3SUmEh\XiycnXzd4lwdg>? M1O5ZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MEWzPVkxLz5{NUC1N|k6ODxxYU6=
SH-SY5Y  NUDHclVXSXCxcITvd4l{KEG|c3H5 NYCzN2hCOjYEoN88[{9uVA>? MXixxsBp NWGyWHA{[2G3c3XzJJN1[XSrc4TpZ4FtdHlic3nncolncWOjboSgdoVlfWO2aX;uJIlvKGKxdHigR3BHNSCjbnSgR3BHM0OPLXnu[JVk\WRiYYDvdJRwe2m|wrC= MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl5NUK3Okc,OjR7N{WyO|Y9N2F-
JJN3 M1q2emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX6wMlEuOTByIN88US=> NIXQdZg4OiCq M{HJbGROW09? MYjpcohq[mm2czDj[YxtKGe{b4f0bEB{dGmpaITsfS=> Mme4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNzN{izO|goRjJ|MUe4N|c5RC:jPh?=
XG-1 NEnJ[3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LOZ|AvOS1zMECg{txO NHnWWng4OiCq MV3EUXNQ MlHabY5pcWKrdIOgZ4VtdCCpcn;3eIg> M33lZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|MUe4N|c5Lz5{M{G3PFM4QDxxYU6=
CD138+  NVHSVIRVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXywMlEuOTByIN88US=> NYTJ[WdRPzJiaB?= M{jOSmROW09? MlXNbY5pcWKrdIOgZ4VtdCCpcn;3eIg> M3HLN|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|MUe4N|c5Lz5{M{G3PFM4QDxxYU6=
XG-1 MkHWSpVv[3Srb36gRZN{[Xl? MVGyM|ExOCEQvF2= NV\CPHcxOjRiaB?= NEPnZ2ZFVVOR Ml:1bY5pcWKrdIOgR2NNOy:PSWCtNe6yKG2UTlGg[ZhxemW|c3nvci=> MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzF5OEO3PEc,OjNzN{izO|g9N2F-
U266 MlfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE[wfowxNjBzLUGwJO69VQ>? Mn;2OFjjiImq NH:2NINFVVOR NV\XWI52cW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjV3MkCwPEc,OjJ3NUKwNFg9N2F-
CRBN60 MkewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV[wMlAyNTFyIN88US=> NVLqVG52PDkkgJno MlzQSG1UVw>? NFjoemxqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjV3MkCwPEc,OjJ3NUKwNFg9N2F-
CRNB75 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWe2UFg4OC5yMT2xNEDPxE1? MWO0PQKBkWh? MWfEUXNQ MVjpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 M1;UTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NUWyNFA5Lz5{MkW1NlAxQDxxYU6=
MM.1S MmH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPidlIxNjBzLUGwJO69VQ>? M1fTXFQ56oDLaB?= MVfEUXNQ NWr1THRSe2mpbnnmbYNidnSueTDpcohq[mm2czDwdo9tcW[ncnH0bY9vKGG2IHPvcoNmdnS{YYTpc45{KGG|IHzve{BieyByLkCx{txO M2TM[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzM{i5N|I4Lz5{MUO4PVMzPzxxYU6=
OPM2 M1rPS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HUNlAvODFvMUCg{txO NH63SZo1QOLCiXi= MXTEUXNQ MmTnd4lodmmoaXPhcpRtgSCrbnjpZol1eyCycn;sbYZmemG2aX;uJIF1KGOxbnPlcpRz[XSrb37zJIF{KGyxdzDhd{AxNjBzzszN M4izV|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzM{i5N|I4Lz5{MUO4PVMzPzxxYU6=
MM.1S Mlm1SpVv[3Srb36gRZN{[Xl? MYOxNEDPxE1? M2rr[|czKGh? NIXtR3NFVVOR MVPzbYdvcW[rY3HueIx6KGSnY4LlZZNmeyC2aHWgdJJwfGWrbjDs[ZZmdCCxZjDDM2VDWM7{IHnzc4Zwem2|wrC= MmjOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF|OEmzNlcoRjJzM{i5N|I4RC:jPh?=
H929 NYrqTGVZTnWwY4Tpc44hSXO|YYm= NInDdlEyOCEQvF2= MUO3NkBp NHvPTotFVVOR M321cZNq\26rZnnjZY51dHliZHXjdoVie2W|IITo[UBxem:2ZXnuJIxmfmWuIH;mJGMwTUKSzsKgbZNw\m:{bYRCpC=> MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTN6OUOyO{c,OjF|OEmzNlc9N2F-
OPM2 MlHUSpVv[3Srb36gRZN{[Xl? MUSxNEDPxE1? MYS3NkBp M1S0O2ROW09? M3jxRpNq\26rZnnjZY51dHliZHXjdoVie2W|IITo[UBxem:2ZXnuJIxmfmWuIH;mJGMwTUKSzsKgbZNw\m:{bYRCpC=> MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTN6OUOyO{c,OjF|OEmzNlc9N2F-
CT26 MlLKSpVv[3Srb36gRZN{[Xl? NHXqZ3QyNzFyIN88US=> MYOyOEBp MYjy[YR2[2W|IITo[UBvfW2kZYLzJI9nKGyrdnWgZ49td26rZYRCpC=> NGHGRXM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOU[zPFk4Pyd-MUm2N|g6Pzd:L3G+
T-cells NF71WmpHfW6ldHnvckBie3OjeR?= NECwZ4IzKHSxIEOg[IF6ew>? NFzhSlZKdmirYnn0bY9vKG:oIFnMMVIheHKxZIXjeIlwdiCrbjDoeY1idiCWIHPlcIx{KG2nYYP1doVlKGGodHXyJFIhfG9iMzDkZZl{KGK7IFXMTXNCNCCHQ{WwJF0hOC5yMEig{txONg>? MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzF4OECxPUc,OjNzNkiwNVk9N2F-
DF15 M1nDR2Z2dmO2aX;uJIF{e2G7 NVrX[FdLPCCqcoO= M1Hpc2lv\HWldHnvckBw\iClZYLlZoxwdi2vZXTpZZRm\CCjaX;sc5Mh\GWpcnHkZZRqd25iaX6gbJVu[W5iRF[xOUBk\WyuczDlfJBz\XO|aX7nJIVRVC22YXfn[YQh[WmxbH;zJIFnfGW{IESgbJJ{KGK7IHz1cYlvd22ndILpZ{BidmGueYPpd{whTUN3MDC9JFAvODJ{IN88UU4> NUPESI1[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0NlU4OjBpPkK4OFI2PzJyPD;hQi=>
DF15 MWPGeY5kfGmxbjDhd5NigQ>? M2rn[|QhcHK| MV;JcoR2[3Srb36gc4Yh[2W{ZXLsc44udWWmaXH0[YQhcWujcn;zJIRm\3KjZHH0bY9vKGmwIHj1cYFvKESIMUWgZ4VtdHNiZYjwdoV{e2mwZzDlVGwufGGpZ3XkJIls[XKxczDh[pRmeiB2IHjyd{BjgSCudX3pco9u\XS{aXOgZY5idHm|aYOsJGVEPTBiPTCwMlAzPCEQvF2u Mki3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh2MkW3NlAoRjJ6NEK1O|IxRC:jPh?=
DF15 NULGe4U3TnWwY4Tpc44h[XO|YYm= NYLQRYZZPCCqcoO= NEj2OlNKdmS3Y4Tpc44hd2ZiQ2LMOE9EWkKQIIXibZF2cXSrbjDsbYdie2VvbXXkbYF1\WRiYXnvcI9{KGSnZ4Lh[IF1cW:wIHnuJIh2dWGwIFTGNVUh[2WubIOg[ZhxemW|c3nu[{BxVE:FLXXQUE11[WepZXSgZYlwdG:|IHHmeIVzKDRiaILzJIJ6KGy3bXnu[ZNk\W6lZTDiZZNm\CCkZYThMYdidGGldH;zbYRie2ViZX76fY1mKG[{YXft[Y51[XSrb36gZ49ueGynbXXueIF1cW:wIHHzd4F6NCCHQ{WwJF0hOC5yMkeg{txONg>? NHnweGY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEO1PFUxPyd-MkizOVg2ODd:L3G+
NAMALWA NHToRVZCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= MUC3NkBpenN? M1r6[WFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTlHNRWxYSSClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJHs{UF22aIntbYRqdmViaX7jc5Jxd3KjdHnvckBi\nSncjC3NkBpenNiYomgd4NqdnSrbHzheIlwdiClb4XueIlv\yxiSVO1NEA:KDBwMEOg{txONg>? M3vNUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|MU[4NFE6Lz5{M{G2PFAyQTxxYU6=
HeLa Mmf6SpVv[3Srb36gZZN{[Xl? MWXJcohq[mm2aX;uJI9nKEmOLUGtZYxxcGFvaX7keYNm\CCQRj3rZZBx[UJiYXP0bZZifGmxbjDpckBJ\UyjIHPlcIx{KGG|c3Xzd4VlKGG|IHLsc4NscW6pIH;mJJA2OC:yNkWgcpVkdGWjcjD0doFve2yxY3H0bY9vNCCLQ{WwJF0hOS5{NzFOwG0v M37C[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5OES1PFUxLz5zN{i0OVg2ODxxYU6=
DF15 NH\XNWtHfW6ldHnvckBie3OjeR?= MmrWNE4xOSC2bzCxJJVO MmSxOUBpenN? MmPjTY5lfWO2aX;uJI9nKGOncnXicI9vNW2nZHnheIVlKGGrb3zvd{Bl\We{YXTheIlwdiCrbjDoeY1idiCGRkG1JINmdGy|IHH0JFAvODFidH:gNUB2VSCjZoTldkA2KGi{czDifUBqdW23bn;icI91KGGwYXz5d4l{ MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDR{NUeyNEc,Ojh2MkW3NlA9N2F-
OPM2 MVLGeY5kfGmxbjDhd5NigQ>? Mn7hNE4xOSC2bzCxJJVO NYf6fYhOPSCqcoO= NEK3[4ZKdmS3Y4Tpc44hd2ZiY3Xy[YJtd25vbXXkbYF1\WRiaXvhdo9{KGSnZ4Lh[IF1cW:wIHnuJIh2dWGwIF;QUVIh[2WubIOgZZQhOC5yMTD0c{AyKHWPIHHmeIVzKDViaILzJIJ6KGmvbYXuc4Jtd3RiYX7hcJl{cXN? NULoT|Z3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0NlU4OjBpPkK4OFI2PzJyPD;hQi=>
DF15 NXfUeYViTnWwY4Tpc44h[XO|YYm= MVewMlAyKHSxIEGgeW0> NUnOOIRVPSCqcoO= MWrJcoR2[3Srb36gc4Yh[2W{ZXLsc44udWWmaXH0[YQhcWujcn;zJIRm\3KjZHH0bY9vKGmwIHj1cYFvKESIMUWgZ4VtdHNiYYSgNE4xOSC2bzCxJJVOKGGodHXyJFUhcHK|IHL5JIludXWwb3Lsc5Qh[W6jbInzbZM> MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDR{NUeyNEc,Ojh2MkW3NlA9N2F-
OPM2 MoK4SpVv[3Srb36gZZN{[Xl? NVnLb3VKOC5yMTD0c{AyKHWP M4Djd|UhcHK| M33veWlv\HWldHnvckBw\iClZYLlZoxwdi2vZXTpZZRm\CCjaX;sc5Mh\GWpcnHkZZRqd25iaX6gbJVu[W5iT2DNNkBk\WyuczDheEAxNjBzIITvJFEhfU1iYX\0[ZIhPSCqcoOgZpkhcW2vdX7vZoxwfCCjbnHsfZNqew>? MoPXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh2MkW3NlAoRjJ6NEK1O|IxRC:jPh?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
CEBPβ; 

PubMed: 21389327     


MM.1S, H929, OPM2, or primary myeloma cells were cultured with DMSO, pomalidomide, or lenalidomide at the indicated concentrations for 3 days. Representative results from 3 independent experiments are shown. Cells were then lysed, and cell lysates were an䲧疝Ỵ疞㧀疜膉痘 瘿뾠ՂᾰƌՂĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒ՂĀ鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ⟸෕䐺痖暼瘿⟸෕ᾰƌ

IKZF1 / IKZF3 / UBE2G1 / CRBN ; 

PubMed: 30234487     


Immunoblot analysis of SKMM2 cells transduced with lentiviral vectors encoding GFP, UBE2G1 and UBE2G1-C90S. Cells were treated with DMSO vehicle control, LEN or POM at the indicated concentrations for 16 hr.

21389327 30234487
Immunofluorescence
IKZF1; 

PubMed: 29496670     


CD34+ cells were treated with DMSO (0.01%), LEN, or POM (1 μM) for 6 hours. The cells were then fixed and stained for IKZF1 (red color), and nuclear counterstaining was performed with DAPI (blue color). The localization of IKZF1 was observed using a Leica䲧疝Ỵ疞㧀疜膉痘 

29496670
In vivo

Pomalidomide enhances the antitumor effect of rituximab against B-cell lymphomas in severe combined immunodeficient mice. Administration of Pomalidomide in combination with rituximab, gives the mice a median survival period of 74 days compared with 58 days of CC5013/rituximab treatment and 45 days of rituximab nonotherapy. The synergistic effect of Pomalidomide and rituximab can be completely abrogated by depletion of NK cells, supporting the proposal that NK cell expansion is one mechanism by which Pomalidomide may augment rituximab antitumor activity. [4]

Protocol

Kinase Assay:

[1]

- Collapse

Inhibition of TNF-α synthesis:

TNF-α inhibitory activity is measured in lipopolysacharide (LPS) stimulated PBMC. Pomalidomide is added to human PBMCs 1 hour prior to the addition of LPS (1 μg/mL) and incubation continued for an additional 18-20 hours. Supernatants are then harvested, and the concentration of TNF-α in the supernatants is determined by ELISA. The concentration of Pomalidomide that inhibits TNF- production by 50% (IC50) is calculated by nonlinear regression analysis. The human whole blood TNF- inhibition assay is run in a similar fashion to the PBMC assay except that heparinized fresh human whole blood is plated directly into microtiter plates.
Cell Research:

[4]

- Collapse
  • Cell lines: Raji, SU-DHL-4 and SU-DHL-10 cell lines
  • Concentrations: Dissolved in DMSO, final concentrations 2.5-40 μg/mL
  • Incubation Time: 24 or 48 hours
  • Method:

    For assessment of cell apoptosis, Lymphoma cell lines are exposed to Pomalidomide (5 μg/mL) for 24 hours or 48 hours. The cells are stained with FITC-labeled Annexin V and propidium iodine. Cell apoptosis is analyzed by multicolor flow cytometric analysis using a fluorescence-activated cell sorter/FACStar Plus flow cytometer. Cells are scored as apoptotic if they are Annexin V–positive and propidium iodine–negative/positive (early and late apoptosis, respectively). For determination of cell proliferation, the Lymphoma cell lines are exposed to Pomalidomide (2.5, 5, 10, 20, and 40 μg/mL) for 24 hours or 48 hours. 1 μCi per well (96-well plate) of [3H]-thymidine is added and cells are incubated for another 18 hours. Cells are then harvested using the Harvest system into the 96-well glass filters and [3H]-thymidine uptake is measured using an automated scintillation counter.


    (Only for Reference)
Animal Research:

[4]

- Collapse
  • Animal Models: Disseminated lymphoma-bearing SCID mice
  • Dosages: 0.5 mg/kg
  • Administration: Injection i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 54 mg/mL (197.62 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+2% Tween 80+ddH2O
For best results, use promptly after mixing.
3mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 273.24
Formula

C13H11N3O4

CAS No. 19171-19-8
Storage powder
in solvent
Synonyms CC-4047
Smiles C1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C(=CC=C3)N

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04191616 Recruiting Drug: Carfilzomib|Drug: Dexamethasone|Drug: Pomalidomide Relapsed or Refractory Multiple Myeloma Amgen August 6 2020 Phase 2
NCT04305444 Recruiting Drug: DTRM-555 Relapsed Chronic Lymphocytic Leukemia|Refractory Chronic Lymphocytic Leukemia|Diffuse Large B Cell Lymphoma|Follicular Lymphoma|Richter''s Transformation Zhejiang DTRM Biopharma April 24 2020 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Is S1567 in the 1% DMSO+30% polyethylene glycol+1% Tween 80 suitable for oral administration?

  • Answer:

    S1567 in 1% DMSO+30% polyethylene glycol+1% Tween 80 is a suspension. This formulation is for oral gavege.

  • Question 2:

    I would like to know if the pomalidomide is racemic or optically active?

  • Answer:

    Our S1567 Pomalidomide is racemic.

E3 ligase Ligand Inhibitors with Unique Features

Tags: buy Pomalidomide | Pomalidomide supplier | purchase Pomalidomide | Pomalidomide cost | Pomalidomide manufacturer | order Pomalidomide | Pomalidomide distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID